RedHill Provides R&D Update
RedHill has elected to terminate RHB-204's U.S. Phase 3 study for Non-tuberculosis Mycobacteria (NTM) disease due to low accrual rate and plans to shift resources to more rapidly advance RHB-107 late-...
1.93 | |
2.05 | |
- | |
2.06 | |
1.85 | |
1.85-49.2 | |
5 863 K | |
2 949 K | |
61 800 K | |
-1.5962 | |
0 | |
2.1499 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
RedHill has elected to terminate RHB-204's U.S. Phase 3 study for Non-tuberculosis Mycobacteria (NTM) disease due to low accrual rate and plans to shift resources to more rapidly advance RHB-107 late-...
TEL AVIV, Israel and RALEIGH, N.C., May 15, 2023 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has ...